AL amyloidosis, caused by a buildup of abnormal protein deposits in tissues and organs, leads to serious health issues if left undiagnosed. The AL amyloidosis diagnostic market consists of tests and services for detecting the presence of amyloid deposits and determining the type of amyloid involved. Amyloidosis diagnostic products include services such as bone marrow biopsy and tests like urine specimen analysis and immunological techniques. Early and accurate diagnosis plays a crucial role in the successful management of AL amyloidosis.


The AL amyloidosis diagnostic market is estimated to be valued at USD 1.068 billion in 2024 and is expected to reach USD 1.693 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.



Key players operating in the AL amyloidosis diagnostic market are Pfizer Inc., Prothena Corporation Plc, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc.



The growing incidence of  AL Amyloidosis Diagnostic Market worldwide is driving the demand for diagnostic services and tests. According to estimates, around 4,500 new cases of AL amyloidosis are diagnosed in the United States every year.



Technological advancements are helping improve diagnostic capabilities. Newer diagnostic methods like microarray analysis of gene expression and mass spectrometry are enabling early and accurate detection of amyloid deposits. This is raising hope for timely treatment interventions and better patient outcomes.



Market Trends



Increasing adoption of novel diagnostic techniques - Tests like immunoprecipitation, histochemistry as well as latest mass spectrometry approaches are gradually replacing conventional light-chain escape measurements and bone marrow biopsies.



Rise in multi-disciplinary care approach - Specialized amyloidosis centers bringing together hematologists, cardiologists and other experts ensure comprehensive diagnosis and management of the condition.



Market Opportunities



Development of non-invasive diagnostic methods - Technologies enabling detection of amyloid deposits without an invasive tissue biopsy can boost early detection rates.



Growing amyloidosis awareness programs - Initiatives by patient advocacy groups to spread awareness about symptoms and importance of prompt diagnosis present significant market potential.



Impact of COVID-19 on AL amyloidosis diagnostic market growth

The COVID-19 pandemic has significantly impacted the AL amyloidosis diagnostic market. During the initial lockdown phase across various countries, routine diagnostic tests and procedures declined significantly due to constraints on resources and movement. This impacted the AL amyloidosis diagnostic procedures as well during this period. However, as lockdowns eased in many parts of the world from mid-2020, the market saw gradual recovery. Still, the fear of contracting infection at hospitals restricted many patients from undergoing non-urgent diagnostic evaluations.



The post-COVID scenario is now more conducive for market growth. Healthcare systems across major markets have strengthened their preparedness and safety protocols to prevent infection spread at facilities. This has boosted patient confidence to seek timely diagnosis and treatment again without fear. Moreover, telehealth emerged as an important tool during the pandemic for remote consultations and follow-ups. This telemedicine trend is likely to see continued adoption for managing AL amyloidosis patients efficiently as well. Manufacturers are also focusing on developing home-based diagnostic kits and services to improve convenience and access. With adequate safety measures in place and innovative solutions, the AL amyloidosis diagnostic market is projected to slowly regain its pre-pandemic growth trajectory in the coming years.



In terms of geographical concentration, North America currently accounts for the largest share of the global AL amyloidosis diagnostic market, supported by continuous technological advancements and widespread medical insurance coverage in the region. Meanwhile, Asia Pacific is identified as the fastest growing regional market owing to rising healthcare expenditures, growing public awareness about the condition, and increasing collaboration between local and international industry stakeholders to enhance diagnostics access. Countries like China, India, Japan, and South Korea are anticipated to drive the extraordinary market growth in Asia Pacific going forward.

Get more insights on – AL Amyloidosis Diagnostic Market

Get this Report in Japanese Language: ALアミロイドーシス診断市場

Get this Report in Korean Language:  AL 아밀로이드증 진단 시장

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )